TOKYO, Dec 18 (Reuters) - Japan’s Shionogi & Co said on Tuesday that it has applied to health regulators in the United States, Canada and Europe for approval of its HIV drug Dolutegravir. Shionogi developed Dolutegravir with a Viiv Healthcare, an AIDS drug joint venture between GlaxoSmithKline and Pfizer, in exchange for its rights to the drug.
the company plans to distribute the drug widely
( z1 plan :ARG0 ( z2 company ) :ARG1 ( z3 distribute :ARG0 z2 :ARG1 ( z4 drug ) :ARG1-of ( z5 wide ) ) )